OverviewSuggest Edit

Axsome Therapeutics is a clinical-stage biopharmaceutical company that develops therapies for the management of central nervous system (CNS) disorders. The Company works on product candidates for the treatment of resistant depression and Alzheimer's disease agitation, complex regional pain syndrome, knee osteoarthritis related to bone marrow lesions, and chronic low back pain related to Modic changes. It is also developing a preclinical product candidate for CNS disorders, including chronic pain.

TypePublic
Founded2012
HQNew York, US
Websiteaxsome.com
Employee Ratings0

Latest Updates

Employees (est.) (Mar 2019)29(+8%)
Job Openings2
Share Price (May 2019)$23.4 (+2%)

Key People/Management at Axsome Therapeutics

Herriot Tabuteau

Herriot Tabuteau

CEO
John Golubieski

John Golubieski

CFO
Robert Niecestro

Robert Niecestro

VP, Head of Regulatory Affairs
Show more

Axsome Therapeutics Office Locations

Axsome Therapeutics has an office in New York
New York, US (HQ)
25 Broadway 9th Floor
Show all (1)

Axsome Therapeutics Financials and Metrics

Axsome Therapeutics Revenue

USD

Net income (Q1, 2019)

(10.6m)

EBIT (Q1, 2019)

(10.4m)

Market capitalization (16-May-2019)

779.3m

Closing stock price (16-May-2019)

23.4

Cash (31-Mar-2019)

42.6m
Axsome Therapeutics's current market capitalization is $779.3 m.
Annual
USDFY, 2016FY, 2017FY, 2018

General and administrative expense

6.3m7.2m9.4m

R&D expense

21.2m20.0m23.5m

Operating expense total

27.5m27.2m32.8m

EBIT

(27.5m)(27.2m)(32.8m)
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

General and administrative expense

1.4m1.5m1.6m1.7m1.7m1.8m2.4m2.4m2.2m2.8m

R&D expense

4.5m5.3m5.6m6.0m5.0m4.5m4.8m5.6m6.0m7.6m

Operating expense total

5.9m6.8m7.2m7.7m6.8m6.3m7.2m8.0m8.2m10.4m

EBIT

(5.9m)(6.8m)(7.2m)(7.7m)(6.8m)(6.3m)(7.2m)(8.0m)(8.2m)(10.4m)
Annual
USDFY, 2016FY, 2017FY, 2018

Cash

36.6m34.0m14.0m

Inventories

2.6m

Current Assets

38.0m35.3m15.2m

Total Assets

38.2m35.6m15.4m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

44.1m38.8m33.9m45.0m38.0m31.7m26.6m20.4m15.2m42.6m

Current Assets

45.1m39.9m34.8m46.2m38.8m32.4m27.8m21.5m15.9m43.8m

Total Assets

45.1m40.0m34.9m46.4m39.0m32.6m27.9m21.7m16.1m43.9m

Accounts Payable

1.8m3.0m3.9m4.7m4.0m2.9m3.9m3.2m4.2m3.4m
Annual
USDFY, 2016FY, 2017FY, 2018

Net Income

(27.2m)(28.9m)(31.0m)

Depreciation and Amortization

20.5k42.6k48.9k

Inventories

(383.9k)

Accounts Payable

2.2m(645.7k)251.8k
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(5.9m)(12.7m)(19.9m)(8.0m)(15.1m)(21.5m)(4.8m)(13.1m)(21.4m)(10.6m)

Depreciation and Amortization

2.1k5.1k10.7k10.1k20.5k31.3k11.9k23.7k36.7k11.4k

Accounts Payable

(61.9k)1.1m2.0m659.5k(42.5k)(1.1m)439.1k(260.3k)731.9k(253.1k)

Cash From Operating Activities

(3.9m)(9.3m)(14.1m)(6.6m)(13.7m)(20.2m)(6.7m)(14.3m)(20.3m)(9.5m)
USDY, 2019

Financial Leverage

2.5 x
Show all financial metrics

Axsome Therapeutics News and Updates

Axsome Therapeutics Reports First Quarter 2019 Financial Results and Provides Business Update

Company to host conference call today at 8:00 AM Eastern

Axsome Therapeutics Announces Expedited Development and Pivotal Status for AXS-05 in the Treatment of Major Depressive Disorder based on FDA Breakthrough Therapy Meeting

Previously completed active-controlled ASCEND trial in MDD now considered as pivotal; sufficient with ongoing STRIDE-1 Phase 3 trial for NDA in MDD

Axsome Therapeutics shares soar on 'breakthrough' FDA status for depression drug

Axsome Therapeutics shares soar on 'breakthrough' FDA status for depression drug

Axsome Therapeutics shares soar after FDA grants breakthrough designation to depression drug

Axsome Therapeutics Inc. shares jumped 7% in premarket trade Wednesday, after the U.S. Food and Drug Administration granted breakthrough therapy designation to a treatment for major depressive disorder. The designation, given to the company's AXS-05 oral, investigational NMDA receptor antagonist, g…

Thinking about buying stock in Apple, Axsome Therapeutics, Luxoft, Netflix or QEP Resources?

NEW YORK, Jan. 8, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AXSM, LXFT, NFLX, and QEP. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Axsome Therapeutics Blogs

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation Content Import Mon, 04/15/2019 - 06:03 Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in Phase 2 Trial in Smoking Cessation April 15, 2019 This…

Axsome Therapeutics Receives FDA Breakthrough Therapy Designation for AXS-05 for the Treatment of Major Depressive Disorder

Designation offers potential for expedited development and review NEW YORK , March 27, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today

Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank

Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank Content Import Wed, 03/06/2019 - 07:07 Axsome Therapeutics Secures $24 Million Growth Capital Loan Facility Led by Silicon Valley Bank March 06, 2019 This release i…

Axsome Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on March 14, 2019

Axsome to host conference call and webcast on Thursday, March 14, 2019 at 8:00 AM Eastern Time NEW YORK , March 05, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system

Axsome Therapeutics Initiates MOMENTUM Phase 3 Trial of AXS-07 in Migraine

First patient enrolled in the MOMENTUM study Trial being conducted under FDA Special Protocol Assessment (SPA) Topline results anticipated in 1Q 2020 NEW YORK , March 04, 2019 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a clinical-stage biopharmaceutical company developing novel

Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine

Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial of AXS-07 in Migraine Content Import Wed, 02/06/2019 - 07:06 Axsome Therapeutics Receives FDA Agreement under Special Protocol Assessment (SPA) for the MOMENTUM Phase 3 Trial o…
Show more

Axsome Therapeutics Frequently Asked Questions

  • When was Axsome Therapeutics founded?

    Axsome Therapeutics was founded in 2012.

  • Who are Axsome Therapeutics key executives?

    Axsome Therapeutics's key executives are Herriot Tabuteau, John Golubieski and Robert Niecestro.

  • How many employees does Axsome Therapeutics have?

    Axsome Therapeutics has 29 employees.

  • Who are Axsome Therapeutics competitors?

    Competitors of Axsome Therapeutics include Y-mAbs Therapeutics, BioSpecifics Technologies and Anavex.

  • Where is Axsome Therapeutics headquarters?

    Axsome Therapeutics headquarters is located at 25 Broadway 9th Floor, New York.

  • Where are Axsome Therapeutics offices?

    Axsome Therapeutics has an office in New York.

  • How many offices does Axsome Therapeutics have?

    Axsome Therapeutics has 1 office.